These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

806 related items for PubMed ID: 18047521

  • 1. Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis.
    Revicki D, Willian MK, Saurat JH, Papp KA, Ortonne JP, Sexton C, Camez A.
    Br J Dermatol; 2008 Mar; 158(3):549-57. PubMed ID: 18047521
    [Abstract] [Full Text] [Related]

  • 2. Adalimumab treatment is associated with improvement in health-related quality of life in psoriasis: patient-reported outcomes from a phase II randomized controlled trial.
    Shikiar R, Heffernan M, Langley RG, Willian MK, Okun MM, Revicki DA.
    J Dermatolog Treat; 2007 Mar; 18(1):25-31. PubMed ID: 17365264
    [Abstract] [Full Text] [Related]

  • 3. Impact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis.
    Revicki DA, Willian MK, Menter A, Gordon KB, Kimball AB, Leonardi CL, Langley RG, Kimel M, Okun M.
    J Dermatolog Treat; 2007 Mar; 18(6):341-50. PubMed ID: 18058494
    [Abstract] [Full Text] [Related]

  • 4. The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study.
    Shikiar R, Willian MK, Okun MM, Thompson CS, Revicki DA.
    Health Qual Life Outcomes; 2006 Sep 27; 4():71. PubMed ID: 17005043
    [Abstract] [Full Text] [Related]

  • 5. Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis.
    Revicki DA, Willian MK, Menter A, Saurat JH, Harnam N, Kaul M.
    Dermatology; 2008 Sep 27; 216(3):260-70. PubMed ID: 18187944
    [Abstract] [Full Text] [Related]

  • 6. Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: efficacy and safety results from REACH, a randomized, placebo-controlled, double-blind trial.
    Leonardi C, Langley RG, Papp K, Tyring SK, Wasel N, Vender R, Unnebrink K, Gupta SR, Valdecantos WC, Bagel J.
    Arch Dermatol; 2011 Apr 27; 147(4):429-36. PubMed ID: 21173304
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1).
    Barker J, Hoffmann M, Wozel G, Ortonne JP, Zheng H, van Hoogstraten H, Reich K.
    Br J Dermatol; 2011 Nov 27; 165(5):1109-17. PubMed ID: 21910713
    [Abstract] [Full Text] [Related]

  • 8. Sleep quality and other patient-reported outcomes improve after patients with psoriasis with suboptimal response to other systemic therapies are switched to adalimumab: results from PROGRESS, an open-label Phase IIIB trial.
    Strober BE, Sobell JM, Duffin KC, Bao Y, Guérin A, Yang H, Goldblum O, Okun MM, Mulani PM.
    Br J Dermatol; 2012 Dec 27; 167(6):1374-81. PubMed ID: 22897348
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of adalimumab among patients with moderate to severe psoriasis with co-morbidities: Subanalysis of results from a randomized, double-blind, placebo-controlled, phase III trial.
    Kimball AB, Bensimon AG, Guerin A, Yu AP, Wu EQ, Okun MM, Bao Y, Gupta SR, Mulani PM.
    Am J Clin Dermatol; 2011 Feb 01; 12(1):51-62. PubMed ID: 21110526
    [Abstract] [Full Text] [Related]

  • 10. Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial.
    Loftus EV, Feagan BG, Colombel JF, Rubin DT, Wu EQ, Yu AP, Pollack PF, Chao J, Mulani P.
    Am J Gastroenterol; 2008 Dec 01; 103(12):3132-41. PubMed ID: 18853973
    [Abstract] [Full Text] [Related]

  • 11. Self-reported health outcomes in patients with psoriasis and psoriatic arthritis randomized to two etanercept regimens.
    Gniadecki R, Robertson D, Molta CT, Freundlich B, Pedersen R, Li W, Boggs R, Zbrozek AS.
    J Eur Acad Dermatol Venereol; 2012 Nov 01; 26(11):1436-43. PubMed ID: 22035157
    [Abstract] [Full Text] [Related]

  • 12. Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal.
    Spuls PI, Hooft L.
    Br J Dermatol; 2012 Oct 01; 167(4):710-3; discussion 714-5. PubMed ID: 23013312
    [Abstract] [Full Text] [Related]

  • 13. Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics.
    Papoutsaki M, Chimenti MS, Costanzo A, Talamonti M, Zangrilli A, Giunta A, Bianchi L, Chimenti S.
    J Am Acad Dermatol; 2007 Aug 01; 57(2):269-75. PubMed ID: 17574299
    [Abstract] [Full Text] [Related]

  • 14. Efficacy of adalimumab in the treatment of psoriasis: a retrospective study of 15 patients in daily practice.
    Sola-Ortigosa J, Sánchez-Regaña M, Umbert-Millet P.
    J Dermatolog Treat; 2012 Jun 01; 23(3):203-7. PubMed ID: 21787203
    [Abstract] [Full Text] [Related]

  • 15. Benefit-risk analysis of adalimumab versus methotrexate and placebo in the treatment of moderate to severe psoriasis: comparison of adverse event-free response days in the CHAMPION trial.
    Reich K, Signorovitch J, Ramakrishnan K, Yu AP, Wu EQ, Gupta SR, Bao Y, Mulani PM.
    J Am Acad Dermatol; 2010 Dec 01; 63(6):1011-8. PubMed ID: 20933301
    [Abstract] [Full Text] [Related]

  • 16. Adalimumab improves health-related quality of life in patients with moderate to severe plaque psoriasis compared with the United States general population norms: results from a randomized, controlled Phase III study.
    Revicki DA, Menter A, Feldman S, Kimel M, Harnam N, Willian MK.
    Health Qual Life Outcomes; 2008 Oct 02; 6():75. PubMed ID: 18831744
    [Abstract] [Full Text] [Related]

  • 17. Once-weekly administration of etanercept 50 mg improves patient-reported outcomes in patients with moderate-to-severe plaque psoriasis.
    Reich K, Segaert S, Van de Kerkhof P, Durian C, Boussuge MP, Paolozzi L, Wajdula J, Boggs R.
    Dermatology; 2009 Oct 02; 219(3):239-49. PubMed ID: 19752505
    [Abstract] [Full Text] [Related]

  • 18. Effect of infliximab on health-related quality of life and disease activity by body region in patients with moderate-to-severe psoriasis and inadequate response to etanercept: results from the PSUNRISE trial.
    Kalb RE, Blauvelt A, Sofen HL, Chevrier M, Amato D, Calabro S, Wang J, Schenkel B, Gottlieb AB.
    J Drugs Dermatol; 2013 Aug 02; 12(8):874-80. PubMed ID: 23986160
    [Abstract] [Full Text] [Related]

  • 19. Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial.
    Lebwohl M, Papp K, Han C, Schenkel B, Yeilding N, Wang Y, Krueger GG.
    Br J Dermatol; 2010 Jan 02; 162(1):137-46. PubMed ID: 19903183
    [Abstract] [Full Text] [Related]

  • 20. Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial.
    Feldman SR, Gordon KB, Bala M, Evans R, Li S, Dooley LT, Guzzo C, Patel K, Menter A, Gottlieb AB.
    Br J Dermatol; 2005 May 02; 152(5):954-60. PubMed ID: 15888152
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 41.